ATS 2021 will feature presentations of original research from accepted abstracts. Mini Symposia and Thematic Poster Sessions are abstract based sessions.
Please use the form below to browse scientific abstracts and case reports accepted for ATS 2021. Abstracts presented at the ATS 2021 will be published in the Online Abstract Issue of the American Journal of Respiratory and Critical Care Medicine, Volume 203, May 3, 2021.
Search Tips:
- Use the keyword search to search by keyword or author's name.
- Filter your search results by selecting the checkboxes that apply.
- Click on "Clear" to clear the form and start a new search. .
Search results will display below the form.
Overprescription of Short-Acting Beta2-Agonists in Asthma Patients from 6 Latin American Countries: Results from the SABINA International Study
Session Title
TP15 - TP015 UPDATES IN ADHERENCE AND TREATMENT OF LUNG DISEASE
Abstract
A1610 - Overprescription of Short-Acting Beta2-Agonists in Asthma Patients from 6 Latin American Countries: Results from the SABINA International Study
Author Block: F. Montero-Arias1, J. Carlos Herrera Garcia2, M. Gallego3, M. Antila4, P. Schonffeldt5, W. Mattarucco6, L. Gallegos7, M. Beekman8; 1Servicio de Neumología, Hospital México, CCSS y Hospital Clínica Bíblica, San José, Costa Rica, 2UISP Unidad de Investigación y Salud de Puebla, Puebla, Mexico, 3Unversidad Tecnológica de Pereira Y Fundación Universitaria Autonoma de las Americas, Respiremos S.A.S–Clinical Comfamiliar, Pereira, Colombia, 4Clinica de Alergia Martti Antila, Sorocaba, São Paulo, Brazil, 5Especialista Medicina Interna y Enfermedades Respiratorias, Instituto Nacional del Tórax ITMS Telemedicina de Chile, Santiago, Chile, 6CEPROSS, San Salvador, Entre Ríos, Argentina, 7AstraZeneca, Mexico City, Mexico, 8AstraZeneca, The Hague, Netherlands.
Rationale: Short-acting β2-agonist (SABA) overreliance is associated with poor asthma outcomes. A lack of patient-level data limits understanding of SABA use in Latin America. The SABA use IN Asthma (SABINA) studies assess the current global burden of SABA use. Here we describe sociodemographics, disease characteristics, and treatment patterns of the Latin American cohort from the SABINA International study.
Methods: In this cross-sectional study, data on prescriber type, investigator-classified asthma severity and symptom control guided by the 2017 Global Initiative for Asthma (GINA 2017), exacerbation history, and prescribed asthma treatments (patients ≥12 years with diagnosis per medical records) in 6 Latin American countries were collected using real-time electronic casereport forms. The primary objective was to describe SABA prescription patterns in asthma patients in the previous year.
Results: Data from 1,096 asthma patients (Argentina [31.6%], Colombia [22.8%], Mexico [13.6%], Chile [13.4%], Brazil [10.4%], and Costa Rica [8.2%]) were analyzed (mean age [standard deviation]: 52.0 [16.6] years; 70% female). Most patients had moderate-to-severe asthma (79.4%), were treated by specialists (87.6%), had a body mass index ≥25 kg/m2 (70.3%), had never smoked (75.6%), and had partial/full healthcare reimbursement (75.8%). A comparable proportion of patients had primary/secondary school (46.1%) and high school/university and/or post-university education (50.4%). Over one-fifth of the patients reported ≥3 comorbidities (21.5%). Asthma was partly controlled/uncontrolled in 61.5% of patients, with 47.4% and 12.7% of patients experiencing ≥1 and ≥3 severe exacerbations, respectively, in the past year. Overall, 39.8% of patients were prescribed ≥3 SABA canisters in the past year, which is considered overprescription; 25.4% of patients received ≥10 SABA prescriptions. As few patients had mild asthma, only 4.7% were prescribed SABA monotherapy. Therefore, most patients (59%) were prescribed add-on SABA, with 63.4% of these patients receiving ≥3 SABA canisters in the past year; 40.2% were prescribed ≥10 canisters as add-on SABA (Table). Inhaled corticosteroid monotherapy was prescribed to 24.2% of patients. Oral corticosteroid bursts were prescribed to 38.5% of patients. SABA canisters were purchased over-the-counter by 17.2% of patients. Of these patients, 80.3% also had SABA prescriptions. Among patients with both SABA purchases and SABA prescriptions, 73.5% and 53.6% were prescribed ≥3 and ≥10 SABA canisters, respectively, in the past year.
Conclusions: Most patients in this Latin American cohort were treated by specialists, likely representing those with better healthcare access. However, prescription for ≥3 SABA canisters in the past year was common (39.8%) and highlights a public health concern.
Author Block: F. Montero-Arias1, J. Carlos Herrera Garcia2, M. Gallego3, M. Antila4, P. Schonffeldt5, W. Mattarucco6, L. Gallegos7, M. Beekman8; 1Servicio de Neumología, Hospital México, CCSS y Hospital Clínica Bíblica, San José, Costa Rica, 2UISP Unidad de Investigación y Salud de Puebla, Puebla, Mexico, 3Unversidad Tecnológica de Pereira Y Fundación Universitaria Autonoma de las Americas, Respiremos S.A.S–Clinical Comfamiliar, Pereira, Colombia, 4Clinica de Alergia Martti Antila, Sorocaba, São Paulo, Brazil, 5Especialista Medicina Interna y Enfermedades Respiratorias, Instituto Nacional del Tórax ITMS Telemedicina de Chile, Santiago, Chile, 6CEPROSS, San Salvador, Entre Ríos, Argentina, 7AstraZeneca, Mexico City, Mexico, 8AstraZeneca, The Hague, Netherlands.
Rationale: Short-acting β2-agonist (SABA) overreliance is associated with poor asthma outcomes. A lack of patient-level data limits understanding of SABA use in Latin America. The SABA use IN Asthma (SABINA) studies assess the current global burden of SABA use. Here we describe sociodemographics, disease characteristics, and treatment patterns of the Latin American cohort from the SABINA International study.
Methods: In this cross-sectional study, data on prescriber type, investigator-classified asthma severity and symptom control guided by the 2017 Global Initiative for Asthma (GINA 2017), exacerbation history, and prescribed asthma treatments (patients ≥12 years with diagnosis per medical records) in 6 Latin American countries were collected using real-time electronic casereport forms. The primary objective was to describe SABA prescription patterns in asthma patients in the previous year.
Results: Data from 1,096 asthma patients (Argentina [31.6%], Colombia [22.8%], Mexico [13.6%], Chile [13.4%], Brazil [10.4%], and Costa Rica [8.2%]) were analyzed (mean age [standard deviation]: 52.0 [16.6] years; 70% female). Most patients had moderate-to-severe asthma (79.4%), were treated by specialists (87.6%), had a body mass index ≥25 kg/m2 (70.3%), had never smoked (75.6%), and had partial/full healthcare reimbursement (75.8%). A comparable proportion of patients had primary/secondary school (46.1%) and high school/university and/or post-university education (50.4%). Over one-fifth of the patients reported ≥3 comorbidities (21.5%). Asthma was partly controlled/uncontrolled in 61.5% of patients, with 47.4% and 12.7% of patients experiencing ≥1 and ≥3 severe exacerbations, respectively, in the past year. Overall, 39.8% of patients were prescribed ≥3 SABA canisters in the past year, which is considered overprescription; 25.4% of patients received ≥10 SABA prescriptions. As few patients had mild asthma, only 4.7% were prescribed SABA monotherapy. Therefore, most patients (59%) were prescribed add-on SABA, with 63.4% of these patients receiving ≥3 SABA canisters in the past year; 40.2% were prescribed ≥10 canisters as add-on SABA (Table). Inhaled corticosteroid monotherapy was prescribed to 24.2% of patients. Oral corticosteroid bursts were prescribed to 38.5% of patients. SABA canisters were purchased over-the-counter by 17.2% of patients. Of these patients, 80.3% also had SABA prescriptions. Among patients with both SABA purchases and SABA prescriptions, 73.5% and 53.6% were prescribed ≥3 and ≥10 SABA canisters, respectively, in the past year.
Conclusions: Most patients in this Latin American cohort were treated by specialists, likely representing those with better healthcare access. However, prescription for ≥3 SABA canisters in the past year was common (39.8%) and highlights a public health concern.
